Trial Profile
A Phase 1b Trial of a Combination of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions
- 18 Mar 2024 Status changed from active, no longer recruiting to completed.
- 02 Jan 2024 Planned End Date changed from 21 Dec 2023 to 21 Dec 2024.
- 24 Oct 2023 Updated results assessing safety and clinical activity of MEKi, binimetinib, and mFOLFIRI in patients (pts) with RAS mt mCRC presented at the 48th European Society for Medical Oncology Congress.